CT103A cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CT103A cells, covering 2024-10-30 to 2024-10-30. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System [EARLY_Phase 1]